Quadrature Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $78.4M | Buy |
2,791,888
+88,052
| +3% | +$2.34M | 0.93% | 21 |
|
|
2025
Q4 | $67.3M | Buy |
+2,703,836
| New | +$68.2M | 0.69% | 39 |
|
|
2025
Q2 | – | Sell |
-386,480
| Closed | -$9.79M | – | 1375 |
|
|
2025
Q1 | $9.79M | Buy |
386,480
+288,455
| +294% | +$7.55M | 0.22% | 110 |
|
|
2024
Q4 | $2.6M | Sell |
98,025
-296,931
| -75% | -$8.05M | 0.05% | 276 |
|
|
2024
Q3 | $11.4M | Sell |
394,956
-222,598
| -36% | -$6.49M | 0.26% | 79 |
|
|
2024
Q2 | $17.3M | Buy |
+617,554
| New | +$17M | 0.29% | 78 |
|
|
2022
Q4 | – | Sell |
-58,196
| Closed | -$2.55M | – | 1074 |
|
|
2022
Q3 | $2.55M | Buy |
+58,196
| New | +$2.83M | 0.08% | 214 |
|
|
2022
Q2 | – | Sell |
-204,107
| Closed | -$10.6M | – | 910 |
|
|
2022
Q1 | $10.6M | Buy |
+204,107
| New | +$10.6M | 0.43% | 64 |
|
|
2021
Q4 | – | Sell |
-410,040
| Closed | -$17.6M | – | 883 |
|
|
2021
Q3 | $17.6M | Buy |
+410,040
| New | +$18.2M | 0.64% | 40 |
|
|
2020
Q4 | – | Sell |
-172,985
| Closed | -$6.02M | – | 1013 |
|
|
2020
Q3 | $6.02M | Buy |
+172,985
| New | +$6.06M | 0.35% | 76 |
|
|
2020
Q1 | – | Sell |
-194,055
| Closed | -$7.21M | – | 655 |
|
|
2019
Q4 | $7.21M | Buy |
194,055
+121,018
| +166% | +$4.31M | 0.27% | 111 |
|
|
2019
Q3 | $2.49M | Buy |
+73,037
| New | +$2.66M | 0.12% | 172 |
|
|
2019
Q2 | – | Sell |
-146,267
| Closed | -$5.9M | – | 614 |
|
|
2019
Q1 | $5.9M | Buy |
+146,267
| New | +$5.86M | 0.5% | 41 |
|
|
2018
Q2 | – | Sell |
-8,829
| Closed | -$297K | – | 673 |
|
|
2018
Q1 | $297K | Buy |
+8,829
| New | +$304K | 0.02% | 480 |
|
|
2017
Q3 | – | Sell |
-166,063
| Closed | -$5.29M | – | 593 |
|
|
2017
Q2 | $5.29M | Buy |
+166,063
| New | +$5.24M | 0.41% | 58 |
|
|
2017
Q1 | – | Sell |
-410,934
| Closed | -$12.7M | – | 809 |
|
|
2016
Q4 | $12.7M | Buy |
410,934
+386,270
| +1,566% | +$11.8M | 0.8% | 22 |
|
|
2016
Q3 | $792K | Sell |
24,664
-56,923
| -70% | -$1.9M | 0.07% | 275 |
|
|
2016
Q2 | $2.73M | Buy |
81,587
+1,121
| +1% | +$35.8K | 0.2% | 122 |
|
|
2016
Q1 | $2.26M | Buy |
80,466
+14,459
| +22% | +$413K | 0.31% | 93 |
|
|
2015
Q4 | $2.02M | Buy |
+66,007
| New | +$2.08M | 0.31% | 92 |
|
|
2015
Q2 | – | Sell |
-15,714
| Closed | -$519K | – | 195 |
|
|
2015
Q1 | $519K | Buy |
+15,714
| New | +$500K | 0.76% | 50 |
|
Other funds holding PFE
VCM
VPM
Quadrature Capital's PFE Position: Q1 2026 in Review
Quadrature Capital increased its Pfizer (PFE) stake by 3.3% in Q1 2026, buying an estimated $2.34M and bringing the position to 2,791,888 shares worth $78.4M. The position accounts for 0.93% of the portfolio, ranked #21.
Quadrature Capital first reported a position in PFE in Q1 2015 and has held it in 21 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Quadrature Capital held 2,791,888 shares of Pfizer worth $78.4M as of Q1 2026.
- Quadrature Capital bought 88,052 Pfizer shares in Q1 2026, an estimated $2.34M.
- Pfizer made up 0.93% of Quadrature Capital's portfolio in Q1 2026, its #21 holding.
- Quadrature Capital first reported a position in Pfizer in Q1 2015 and has held it in 21 quarters since.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.